Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/jcm11113192
Keywords
brain natriuretic peptide; heart failure; diagnosis; prognosis; therapy
Categories
Ask authors/readers for more resources
BNP and NT-proBNP play a key role as serum biomarkers in the management of heart failure. They can be used for diagnosis, prognostic stratification, monitoring and guiding therapy of HF, as well as evaluating the efficacy of new therapeutic strategies. However, their use is still limited due to the controversy surrounding their use in different clinical settings.
Brain natriuretic peptide (BNP) and its inactive N-terminal fragment, NT-proBNP, are serum biomarkers with key roles in the management of heart failure (HF). An increase in the serum levels of these peptides is closely associated with the pathophysiological mechanisms underlying HF such as the presence of structural and functional cardiac abnormalities, myocardial stretch associated with a high filling pressure and neuro-hormonal activation. As BNP and NT-proBNP measurements are possible, several studies have investigated their clinical utility in the diagnosis, prognostic stratification, monitoring and guiding therapy of patients with HF. BNP and NT-proBNP have also been used as criteria for enrollment in randomized trials evaluating the efficacy of new therapeutic strategies for HF. Nevertheless, the use of natriuretic peptides is still limited in clinical practice due to the controversial aspect of their use in different clinical settings. The purpose of this review is to discuss the main issues associated with using BNP and NT-proBNP serum levels in the management of patients with HF under current clinical and therapeutic scenarios.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available